+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: Clinical and endometrial responses



Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: Clinical and endometrial responses



Maturitas 26(2): 103-111



Objective: Our purpose was to compare the effects of a new estradiol-releasing vaginal ring with progesterone given as a vaginal suppository, versus the efficacy, safety and acceptability of an intrauterine device releasing levonorgestrel combined with estradiol, delivered transdermally from a patch. Climacteric symptoms, bleeding pattern and endometrial histologic features were studied. Methods: Fifty six parous, postmenopausal women with urogenital symptoms were allocated in two groups for one year: 28 women receiving estradiol by a vaginal ring and a 100 mg vaginal progesterone suppository 7 days every month and 28 women receiving a continuous transdermal daily dose of 50 mu-g of estradiol with a levonorgestrel-releasing intrauterine device inserted. All the patients were subjected to vaginosonographic examination followed by thorough pathological examination of the uterine curetting samples. Results: A mean endometrial thickness (double layer) of 2.9 and 3.0 mm, respectively, was found to be predictive of normal endometrium. Both treatment regimens effectively relieved climacteric symptoms. Endometrial proliferation was not observed. Spotting was more common in the intrauterine device group than in the vaginal ring group. Conclusions: Treatment of urogenital symptoms in postmenopausal women with these two forms of hormone replacement therapy is shown to be an effective and safe method, exhibiting advantages over other methods of treatment.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 009662640

Download citation: RISBibTeXText

PMID: 9089559

DOI: 10.1016/s0378-5122(96)01087-0


Related references

Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: Clinical and endometrial responses. American Journal of Obstetrics and Gynecology 172(1 PART 1): 114-119, 1995

A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response. International Journal of Fertility and Menopausal Studies 41(6): 522-527, 1996

Studies on a vaginal ring releasing levonorgestrel at an initial rate of 27 micrograms/24 h when used alone or in combination with transdermal systems releasing estradiol. Contraception 50(1): 87-100, 1994

Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone. Acta Obstetricia Et Gynecologica Scandinavica. 77(7): 758-763,., 1998

Randomized comparison of a new estradiol-releasing vaginal ring versus estriol vaginal pessaries. American Journal of Obstetrics and Gynecology 173(2): 670-671, 1995

Effects of levonorgestrel-releasing intrauterine system on endometrial estrogen and progesterone receptors in patients with endometrial hyperplasia. Nan Fang Yi Ke Da Xue Xue Bao 32(9): 1350-1354, 2013

Vaginal flora changes on Pap smears after insertion of levonorgestrel-releasing intrauterine device. Contraception 83(4): 352-356, 2011

Ovulation and fertility after progesterone releasing intra vaginal device progesterone releasing intra vaginal device plus gonadotropin releasing hormone and gonadotropin releasing hormone in anestrous buffaloes. Theriogenology 21(6): 859-868, 1984

Bleeding and ovulation control with use of a small contraceptive vaginal ring releasing levonorgestrel and estradiol. Contraception 20(1): 11-18, 1979

Percutaneous estradiol gel with an intrauterine levonorgestrel releasing device or natural progesterone in hormone replacement therapy. Maturitas. 26(3): 211-217, 1997

The effect of a levonorgestrel-releasing intrauterine device on human endometrial oestrogen and progesterone receptors after one year of use. Human Reproduction 14(4): 970-975, 1999

Vaginal danazol for women with rectovaginal endometriosis and pain symptoms persisting after insertion of a levonorgestrel-releasing intrauterine device. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics 113(2): 116-119, 2011

Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia. Reproductive Sciences 22(3): 329-334, 2015

Clinical investigation of low dose levonorgestrel releasing vaginal ring. Sheng Zhi Yu Bi Yun 7(3): 62-65, 1987

Clinical investigation of a low-dose levonorgestrel-releasing vaginal ring. Fertility and Sterility 46(4): 626-630, 1986